Blood Cancer Video Library - Brody - Mantle Cell Lymphoma - Outcomes CAR T Cell Therapy Trials

Article and Video CATEGORIES

Cancer Journey

ABOUT

ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology Cancer (Oncology), Hematology-Oncology, The Mount Sinai Hospital

Blood Cancer Video Library - Brody - Mantle Cell Lymphoma - Outcomes CAR T Cell Therapy Trials

dbrock

Wed, 05/20/2020 - 16:44

Author

Joshua Brody, MD

Click to Download Transcript

We are happy to bring you updates to the GRACE Blood Cancer Video Library.

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai Hospital joins us to discuss updates from ASH 2019.

For this video, Dr. Brody shares information on Mantle Cell Lymphoma, and the exciting outcomes from CAR-T Cell therapy trials.

To join the conversation, visit https://cancergrace.org/forum.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.